Building Efficient Enzymatic Conjugation Processes for Site-Specific ADC Development - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Building Efficient Enzymatic Conjugation Processes for Site-Specific ADC Development

11:30 am - Wednesday 14th October 2026

Surveying site-specific conjugation techniques and the shift towards enzymatic approaches for greater precision and control
Examining enzymatic conjugation additional manufacturing complexity to identify where process efficiencies can be gained
Evaluating the production, purification, and analytical workflow for a case study glycan-engineered ADCs, highlighting how enzyme-driven steps (e.g., EndoS2) improves scalability

Speakers:

Jared Mattos

Jared Mattos

Principal Scientist

Xcellon Biologics